NCT06035861View on ClinicalTrials.gov

Endothelial Cell Activation and Total Pulmonary Resistance in PAH

NANot yet recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Pulmonary Artery Hypertension
Interventions
DRUG

XBD173

Participants will be treated with XBD173 90mg twice daily for 6 weeks

All Listed Sponsors
lead

Imperial College London

OTHER

NCT06035861 - Endothelial Cell Activation and Total Pulmonary Resistance in PAH | Biotech Hunter | Biotech Hunter